Meet Our Team

Monument Tx is led by a highly experienced team of executives with direct experience designing and managing hundreds of cognitive clinical trials.

Monument Therapeutics JB

Dr Jenny Barnett, Chief Executive Officer
Jenny has an MA in Experimental Psychology from Oxford University, a PhD in the epidemiology of schizophrenia from the University of Cambridge, and completed post-doctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She joined Cambridge Cognition in 2008 and worked in the clinical trial, healthcare and R&D functions before joining the senior management team in 2014 and becoming CSO in 2016. She has worked on the design and analysis of more than 100 cognitive trials and is the author of 60+ scientific publications and six patents. She has led IP strategy, KOL networking and the scientific validation of medical devices for regulatory approval.

Monument Therapeutics KG

Dr Kiri Granger, Chief Scientific Officer
Kiri is an internationally-recognised expert in the design of clinical trials for CNS disorders, particularly schizophrenia. As Director of Neuroscience at Cambridge Cognition, Kiri provided consultancy to over 50 drug development companies on more than 100 clinical trials and was the lead scientist on a number of successful programmes. Kiri chaired the ICSTM working group on schizophrenia clinical trials and is currently an Assistant Professor at the University of Nottingham, Department of Psychology where she is involved in on-going collaborative projects following her PhD research in cognitive and behavioural markers of schizophrenia and anxiety disorders.

Monument Therapeutics SC

Sheryl Caswell, Head of Development
Sheryl graduated in Medical Microbiology and has since worked exclusively in the clinical research arena for over twenty five years .  She has successfully led and managed clinical development programmes across a range of therapeutic indications, with a recent focus on working in small biotech companies within a small team designing and conducting development programmes for products at an early phase of development.

Monument Leadership Photos Final-06

Dr Mark Treherne, Chair
Commercial research scientist with over 25 years’ experience in the discovery of novel treatments for diseases of the nervous system. To date has helped to raise over £200 million for early-stage biotechnology companies. Left Pfizer to set up Cambridge Drug Discovery and sold it to BioFocus plc. Out licensed therapeutic assets for upfront payments, milestones and royalties exceeding £1.5 billion.

Fiona Cree, Clinical Development Advisor
Fiona is COO of Cambridge Cognition and leads the Clinical Science and Operations teams.  She has over twenty five years’ experience in both multi-national pharmaceutical companies and biotech SMEs. This includes roles of increasing responsibility in clinical development – both early and late stage assets – across multiple therapeutic areas as well as global clinical operations and project leadership, primarily with GSK.  Immediately prior to joining Cambridge Cognition she worked with a biotech company focussing on the development of a drug and diagnostic for Alzheimer’s disease.